Reuters logo
REFILE-PTC Therapeutics to buy Marathon's controversial DMD drug
2017年3月16日 / 中午11点47分 / 8 个月前

REFILE-PTC Therapeutics to buy Marathon's controversial DMD drug

(Adds media packaging code)

March 16 (Reuters) - PTC Therapeutics Inc said on Thursday that it would buy the rights to Marathon Pharmaceuticals Llc’s controversial Duchenne muscular dystrophy drug, Emflaza, for $140 million upfront.

The U.S. Food and Drug Administration in February approved the steroid for the devastating muscle-wasting disease that mainly affects young boys. The drug has been available outside the United States for decades.

Northbrook, Illinois-based Marathon has come under fire after saying the drug would carry a list price of $89,000 per year.

PTC said it expects the deal to close in the second quarter. (Reporting by Natalie Grover in Bengaluru; Editing by Savio D‘Souza)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below